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The research of chitosan-based nanogel for biomedical applications has grown exponentially in the last
years; however, its biocompatibility is still insufﬁciently reported. Hence, the present work provides a
thorough study of the biocompatibility of a glycol chitosan (GC) nanogel. The obtained results showed
that GC nanogel induced slight decrease on metabolic activity of RAW, 3T3 and HMEC cell cultures,
although no effect on cell membrane integrity was veriﬁed. The nanogel does not promote cell death
by apoptosis and/or necrosis, exception made for the HMEC cell line challenged with the higher GC
nanogel concentration. Cell cycle arrest on G1 phase was observed only in the case of RAW cells. Remark-
ably, the nanogel is poorly internalized by bone marrow derived macrophages and does not trigger the
activation of the complement system. GC nanogel blood compatibility was conﬁrmed through haemolysis
and whole blood clotting time assays. Overall, the results demonstrated the safety of the use of the GC
nanogel as drug delivery system.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Nanoparticles have been largely researched as drug nanocarri-
ers, yet their interaction with cells and extracellular environment
is still poorly explored. The evaluation of the potential effects of
drug delivery devices on the biological systems is indeed a crucial
requirement in the development of nanomedicines: cytotoxicity,
haematocompatibility (haemolysis and complement activation),
inﬂammatory response; biodegradability and potential cytotoxicity
of the degradation products, cellular uptake and intracellular fate,
in vivo biodistribution studies, all assist in allowing a better deﬁni-
tion of the biological properties of the novel polymers and their
polymeric nanoparticles. (Gaspar and Duncan, 2009; Naahidi
et al., 2013; Rodrigues et al., 2012) The so called ‘‘biocompatibility’’
is largely dependent on the physical and chemical properties of the
nanoparticles (size, shape and surface characteristics), as well as on
the used raw material (Liu et al., 2013; Naahidi et al., 2013).The use of polymeric nanoparticles based on chitosan has been
extensively reported in biomedical applications, due to its interest-
ing characteristics. Non-toxicity, biocompatibility, biodegrad-
ability, antibacterial activity, mucoadhesiveness and permeation
enhancing properties are among the features that have been
reported, the cationic character being responsible for some of them
(Bernkop-Schnurch and Dunnhaupt, 2012; Croisier and Jérôme,
2013). Although often claimed as biocompatible, more comprehen-
sive studies are required for a proper understanding of the biologi-
cal effects of this polymer and of its nanoformulations.
As reported previously, a polymeric nanoparticle made of glycol
chitosan (GC), here designated GC nanogel, has been synthesized in
our laboratory by chemical grafting hydrophobic chains on the GC
backbone, yielding an amphiphilic polymer capable of self-assem-
bling in aqueous environment (Pereira et al., 2013). The present
work focuses on the detailed evaluation of the biocompatibility of
this nanogel. For this purpose, in vitro cell toxicity of the GC nanogel
was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and lactate dehydrogenase
(LDH) release assays to gauge the nanogel cytotoxicity. Induction
of apoptosis and/or cell cycle arresting was tested through ﬂow
cytometry. The complement activation was semi-quantiﬁed by
western blot, analysing the degradation of the C3 factor. Interaction
with murine macrophages was observed through confocal
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ed through haemolysis and whole blood clotting time assays.2. Experimental
2.1. Materials
Glycol chitosan (GC, G7753), mercapto hexadecanoic acid
(MHDA), N-hydroxysulfosuccinimide (NHS) and 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT),
NADH, pyruvate, haemoglobin from bovine blood and Drabkin’s
reagentwere acquired from Sigma–Aldrich. 5/6-Carboxyﬂuorescein
succinimidyl ester was purchased from Thermo Scientiﬁc. Cell Cul-
ture reagents and culture medium were purchased from Biochrom.
2.2. Nanogel self-assembling
GC nanogel was synthesized and characterized as previously
reported (Pereira et al., 2013). Brieﬂy, GC nanogel was prepared
by conjugation of the mercapto hexadecanoic acid (MHDA) to GC,
through a carbodiimide reaction. Nanogel dispersions used in the
different experiments were obtained after dispersing the lyophi-
lized reaction product in distilled water, under magnetic stirring
at 50 C for 48 h, and passed through a cellulose acetate syringe ﬁl-
ter (pore size 0.45 lm).
2.3. Cell cultures
3T3 ﬁbroblasts and mouse leukaemic monocyte macrophage
(RAW 264.7) cell lines were maintained in DMEM supplemented
with 10% bovine calf serum or fetal bovine serum (FBS), respective-
ly, 100 IU/mL penicillin and 0.1 mg/mL streptomycin. Human
microvascular endothelial cells (HMEC) were grown in RPMI-
1640 supplemented with 10% FBS, Epidermal Growth Factor
(EGF, 10 ng/mL), Hydrocortisone (1 lg/mL), 100 IU/mL penicillin
and 0.1 mg/mL streptomycin. All cell lines were cultured as a
monolayer in a humidiﬁed atmosphere containing 5% CO2 at 37 C.
Murine Bone Marrow-Derived Macrophages were collected
from femoral and tibial mouse bone marrow using a previously
published protocol (Carvalho et al., 2011; Cerca et al., 2011).
Brieﬂy, mouse long bones were extracted from the mousse under
aseptic conditions and ﬂushed with RPMI-1640. The resulting cell
suspension was centrifuged at 500g during 10 min. The cell pellet
was resuspended in RPMI-1640 supplemented with 10 mM HEPES,
10% heat-inactivated FBS, 60 lg/mL penicillin/streptavidin,
0.005 mM b-mercaptoethanol (RPMI complete medium) and 10%
L929 Cell Conditioned Medium (LCCM). To remove adherent bone
marrow cells, the cell suspension was incubated overnight at
37 C and 5% CO2 atmosphere in a Petri dish. The non-adherent
cells were collected, centrifuged at 500g (10 min) and seeded in
24 well plates at 5  105 cells per well in RPMI complete medium
containing 10% of LCCM and incubated at 37 C in a 5% CO2 atmo-
sphere. Four days after seeding 10% of LCCM was re-added to the
cultures. The culture medium was replaced with fresh RPMI com-
plete medium containing 10% LCCM on day 7. After 10 days in cul-
ture, cells were completely differentiated into macrophages.
2.4. In vitro cell toxicity
2.4.1. MTT assay
The cytotoxicity of GC nanogel was evaluated by using the
quantitative colorimetric MTT assay. Cells were seeded onto
24-well cell culture plates at a density of 1  104 cells per well
for 3T3 and RAW and of 2  104 for HMEC, and left adhering in0.5 mL of culture medium overnight. Afterwards, the cells were
incubated with nanogel dispersions at 0.1 and 0.5 mg/mL in fresh
culture medium containing 25% of distilled water (v/v). Cells culti-
vated in medium with or without 25% of distilled water (v/v)
(without nanogel) were used as controls. After 24, 48 and 72 h
the metabolic activity was measured adding MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide). The
tetrazolium salt is reduced by metabolically active cells using
mitochondrial succinate dehydrogenase enzymes (Mosmann,
1983). The MTT solution (0.5 mg/mL in PBS) was carefully removed
from each well and the resulting dark blue formazan crystals were
solubilized in dimethyl sulfoxide and quantiﬁed spectrophotomet-
rically at 570 nm. The experiments were performed in triplicate
and the metabolic activity results were shown as percentage of
the values obtained at 0 h time point.
2.4.2. LDH release assay
Cytotoxicity can also be assessed by the degree of membrane
damage. The LDH release assay measures the membrane integrity
as function of the amount of cytoplasmic LDH leaked into the cul-
ture medium. The conversion of NADH and pyruvate into NAD+ and
lactate catalysed by LDH is the basis of the method (Rodrigues
et al., 2012). Cells were seeded in 12-well plate at a density of
the 2  105 cells per well for 3T3 and HMEC and 1  105 for
RAW and allowed to settle overnight in 0.5 mL of culture medium.
The cells were treated with nanogel dispersions with a concentra-
tion of 0.1 and 0.5 mg/mL, in fresh culture medium containing 25%
of distilled water (v/v). Untreated cells, exposed to 20% DMSO (v/v)
or 25% distilled water (v/v) in culture media were used as controls.
At the 24 and 48 h time points the culture medium from each well
was collected and centrifuged at 13,000 rpm for 1 min and the cell
free supernatant was collected and stored on ice for further extra-
cellular LDH measurement. The respective cells were scraped with
the aid of a Tris solution 15 mM and lysed through sonication.
Supernatants of centrifuged samples were used to quantify the
intracellular LDH. Samples of extracellular (40 lL) or intracellular
(10 lL) LDH were plated into a new microplate and 250 lL of the
NADH solution 0.31 mM in phosphate buffer 0.05 M, pH7.4 added
to each well. Finally, 10 lL of a 8.96 mM pyruvate solution in phos-
phate buffer (substrate solution) was added and immediately
afterwards the variation of the absorbance at 340 nm was read in
a microplate spectrophotometer, as to determine the rate of NADH
consumption (slope of the line). LDH leakage was expressed as the
ratio between extracellular and total LDH, corresponding the
inverse value to the cell membrane integrity. Untreated cells were
used as a reference for the estimation of the maximum membrane
integrity. Each experiment was performed in triplicate.
2.5. Apoptosis assay
The FITC Annexin V Apoptosis Detection Kit was used to deter-
mine apoptotic cell membrane changes in 3T3, HMEC and RAW cell
lines. Cells (2  105/well) were seeded in a 12-well plate and left
adhering overnight. The cells were then incubated with nanogel
dispersions at 0.1 and 0.5 mg/mL in fresh culture medium contain-
ing 25% of distilled water (v/v). A negative control assay was car-
ried out without nanogel (the dilution with 25% of distilled water
had no effect on the assay outcome), while H2O2 was used as posi-
tive control for apoptosis using different incubation times and con-
centrations according to the cell line (0.5 mM for 6 h – RAW;
0.2 mM for 24 h – HMEC and 5 mM for 3 h – 3T3) (Piao et al.,
2011; Wang et al., 2007). After 24 h the cells were treated with
250 lL trypsin/EDTA 0.25%/0.02% in PBS for 2 min at 37 C. The cell
suspension was transferred to ﬂow cytometry sample tubes (Beck-
man Coulter) and washed twice with cold PBS. Double staining
with FITC-Annexin V/PI was performed as recommended by the
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sample was incubated with 40 lL of the work solution (1.8 lL of
the Annexin V and PI diluted in 36.4 lL of the annexin V binding
buffer) for 15 min at room temperature, in the dark. Finally,
200 lL of annexin V binding buffer was added to the samples that
were then analysed by ﬂow cytometry using a Coulter Epics XL
Flow Cytometer (Beckman Coulter Inc., Miami, FL, USA).
2.6. Cell cycle analysis
To evaluate the effect of GC nanogel on cell cycle, 3T3 and RAW
cells were seeded at a density of 5  104 cells per well, while HMEC
cells were cultured at 1  105, in 6-well plates, in 2 mL of the
respective culture medium. In the following day, medium was
replaced by GC nanogel dispersions with concentrations of 0.1
and 0.5 mg/mL, in 2 mL of fresh culture medium containing 25%
of distilled water (v/v). An additional condition without nanogel
was carried out as a negative control (the dilution with 25% of dis-
tilled water had no effect on the assay). After 24 h, cells were tryp-
sinised and processed for ﬂow cytometry analysis. In summary, the
collected cells and the respective culture mediumwere centrifuged
and washed with PBS. The cell suspension was kept on ice for
15 min. Ice cold absolute ethanol was used to ﬁx the cells during
15 min on ice. After washing with PBS to remove residual ethanol,
the cells were treated with RNase A (20 lg/mL) during 15 min at
37 C. PI staining solution was added at least 15 min before sample
analysis on the ﬂow cytometer. Cell cycle progression of at least
20,000 single cells per sample was analysed by ﬂow cytometry
using a Coulter Epics XL Flow Cytometer (Beckman Coulter Inc.,
Miami, FL, USA) and analysed by using the FlowJo Analysis Soft-
ware (Tree Star, Inc., Ashland, OR, USA).
2.7. Complement activation
Complement cascade was studied as reported previously
(Lozano et al., 2011) and based on the NCL (Nanotechnology Char-
acterization Laboratory) protocol for qualitative determination of
total complement activation by Western blot analysis. Brieﬂy, a
pool of human plasma from healthy donors was incubated with
1 mg/mL of GC nanogel in the presence of veronal buffer. Equal vol-
umes (50 lL) of plasma, buffer and sample were mixed and incu-
bated at 37 C for 60 min. Cobra venom factor from Quidel
Corporation (San Diego, CA, USA), and PBS were used as positive
and negative controls, respectively. Proteins were resolved by
10% SDS–PAGE, and then transferred to a membrane (Immun-Blot
PVDF Membrane, Biorad, Hercules, USA) using the transblot
semidry BioRad transfer equipment (Trans blot SD, BioRad, Her-
cules, USA). The membranes were incubated for 90 min with a
mouse monoclonal antibody against human C3 diluted 1:1000
(Abcam, Cambridge, UK), washed and incubation with secondary
polyclonal goat anti-mouse IgG antibodies conjugated with alka-
line phosphatase diluted 1:2000 (Dako, Glostrup, Denmark). The
membrane was ﬁnally revealed with 5-Bromo-4-Chloro-3-Indolyl
Phosphate (BCIP) (Sigma). For further analysis, membranes were
scanned with ChemiDoc™XRS + System (Bio-Rad; Hercules, CA).
The percentage of the lower band was then quantiﬁed with Image
Lab™ Software 3.0.
2.8. Confocal laser scanning microscopy
GC nanogels were labelled with 5/6-carboxyﬂuorescein succin-
imidyl ester (NHS-Fluorescein), through an amide linkage, in order
to study their cellular uptake by murine macrophages. In detail, the
NHS-Fluorescein was dissolved in DMSO, at a concentration of 1%.
The molar ratio of NHS-Fluorescein carboxylic groups to the GC
nanogel free amine groups was 0.25. The dye was added to astirred nanogel suspension at a concentration of 1 mg/mL in PBS.
The reaction was allowed to occur overnight at room temperature,
in the dark. The reaction mixture was thoroughly dialysed (MW
cutoff 10–12 kDa) against distilled water to remove free NHS-
Fluorescein. As to verify the absence of free dye, the ﬁnal solution
of NHS-Fluorescein labelled nanogel was puriﬁed by centrifugation
through a 10 kDa MW cutoff ﬁlter.
Murine macrophages were seeded at a density of 5  105 cells
per well in a 24 well plate (with a coverslip in each well), and left
adhering overnight. The cells were incubated with 0.2 mg/mL of
each NHS-Fluorescein labelled nanogel suspension in culture medi-
um containing 25% of water v/v. After 6 h, the coverslips were
washed twice with PBS at room temperature and the cells were
ﬁxed with paraformaldehyde 2% for 25 min. After washing the cells
twicewith PBS twice, 40,6-diamidino-2-phenylindole (DAPI, 120 ng/
mL) was used to stain the nucleus for 3 min at room temperature.
After washing the preparations were observed in a confocal laser
scanning microscope Leica SP2 AOBS SE (Leica Mycrosystems,
Germany).
2.9. Haemocompatibility studies
The whole blood was collected from three independent healthy
donors using citrated blood collection tubes.
2.9.1. Haemolysis index
The haemolysis assay was performed in agreement to the pro-
cedure described by the American Society for Testing Materials
(ASTM F756-00, 2000), with slight modiﬁcations. Brieﬂy, 0.5 mL of
diluted blood at 10 mg/mL of haemoglobin concentration was
added to 3.5 mL of the nanogel solution in PBS at 0.5 mg/mL and
0.1 mg/mL and incubated at 37 C for 3 h. The tubes were gently
inverted at each 30 min to homogenize the mixture. Ultrapure
water and Phosphate-buffered saline (PBS) were used as positive
and negative control, respectively. Then, the suspension was cen-
trifuged at 750g for 15 min. 0.5 mL of the resulted supernatant
was joined to a 0.5 mL Drabkin’s reagent and left 15 min at room
temperature. Finally, the absorbance was read at 540 nm. The hae-
moglobin concentration of the freshly derived human blood was
calculated using a calibration curve previously prepared with hae-
moglobin from bovine blood.
2.9.2. Whole blood clotting time
Whole blood kinetic clotting times of nanogel samples was per-
formed as described by Leitao et al. (2013). Previously, the clotting
was induced by addition of 10% 0.1 M CaCl2 to whole blood. The
nanogel samples at 0.1 and 0.5 mg/mL, glass microspheres
(positive control) and 25% v/v of PBS (negative control) in a 24-well
polystyrene microtitter plate were incubated for 0, 5, 10, 20 and
30 min at room temperature with 150 lL of activated whole blood.
At the end of each time point, 3 mL of distilled water was added to
the well and incubated for 5 min, in order to lyse the red blood
cells (and consequent haemoglobin release) that were not
entrapped in the thrombus. 200 lL of the supernatant was trans-
ferred to a 96-well polystyrene microtitter plate to measure the
concentration of the released heamoglobin by spectrophotometric
analysis at 540 nm. All the samples were studied in triplicate.
2.10. Statistical analysis
The results were expressed as mean ± SD of 3 independent
experiments (n = 3). Statistical signiﬁcances were performed
applying t-test or two-way ANOVA tests through Prism software
(GraphPad software version 5.00, USA). Signiﬁcance of the results
is indicated according to P values with one, two and three of the
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P < 0.0001, respectively).3. Results
3.1. Cytotoxicity studies
3.1.1. Metabolic activity
The cytotoxicity of the GC nanogel was assessed by MTT assay
using a set of cell lines; slightly different results were obtained
with each one (Fig. 1). The control with culture medium diluted
with 25% of water presents a lower cell growth as compared to
the straight medium, an effect probably due to the dilution of
the nutrients. It must be remarked that in none of the tested nano-
gel concentrations the mitochondrial activity was lower than the
one observed at time zero, indicating that the GC nanogel did notFig. 1. Effect of GC nanogel at 0.1 and 0.5 mg/mL after at 24, 48 and 72 h of
incubation with 3T3, HMEC and RAW cell lines, assessed by MTT assay and
expressed taking as reference the initial value. Statistical differences are deter-
mined through a 2-way ANOVA and represented by (+) for the differences between
cell culture medium (Control) and 25% of water content (v/v) into the well; whereas
the differences between 25% H2O and both concentrations of nanogel (NG 0.1 and
NG 0.5) are shown as (#); ﬁnally, concerning cell growth over the time, comparing
0 h incubation time with remaining incubation times for each condition, the
statistical differences are presented as (⁄).induce cell death. On the other hand, all tested cell lines showed
a lower metabolic activity in the presence of the nanogel when
compared with the diluted medium control. A nanogel dose depen-
dent effect on decreasing of cell proliferation rate was exhibited by
HMEC (at 48 and 72 h incubation time), while no such correlation
was observed for 3T3 an RAW cells. The HMEC and RAW cell lines
were clearly more susceptible to nanogel treatment, mainly for
later incubation times.
3.1.2. Cell membrane integrity
The potential cytotoxicity of the GC nanogel was also evaluated
by measuring the cell membrane integrity through LDH leakage
quantiﬁcation. As shown in Fig. 2, the GC nanogel in concentrations
of 0.1 and 0.5 mg/mL did not affect the cell membrane integrity,
since a signiﬁcant LDH release to the culture medium was
observed only in the positive control (20% of DMSO).
3.2. Apoptosis assay
Annexin V FITC/propidium iodide dual staining was used to
investigate the inﬂuence of GC nanogel on cell death induction.
This assay is based on the observation since early stages of apopto-
sis of the phosphatidylserine translocation to the external surface
of the plasma membrane. Annexin V was used as a sensitive probeFig. 2. Effect of GC nanogel at 0.1 and 0.5 mg/mL after 24 and 48 h of incubation
with 3T3, HMEC and RAW cells on the amount of LDH released to culture medium.
Cell culture medium and 20% of DMSO were used as negative and positive control,
respectively. Statistical differences were found by a t-test in each time of incubation
between negative control and 25%H2O or 20% DMSO are shown as (⁄); while
differences between 25% H2O and nanogel samples (NG 0.1 and NG 0.5) are
represented as (#).
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high afﬁnity to phosphatidylserine. Cells in later stages of apopto-
sis (Annexin V+/PI+) or necrosis (Annexin V/PI+) were identiﬁed
through detection of PI binding to nuclear DNA allowed by loss
of cell membrane integrity (Koopman et al., 1994; Vermes et al.,
1995). Viable and early apoptotic cells were recognized through
Annexin V/PI and Annexin V+/PI staining pattern, respectively.
As shown in Fig. 3, the percentage of apoptotic and late-apoptotic
cells incubated with the nanogel was not signiﬁcantly different
from the negative control, exception made for the HMEC cell line,
which displays a slight increase in the Annexin positive cells. A
dose dependent effect on apoptosis induction was indeed observed
in this case.
3.3. Effect of the nanogel on cell cycle arrest
Cell cycle analysis was performed to ascertain whether cell
growth inhibition observed in the MTT assay was correlated with
cell cycle arrest, since no effect on cell death by apoptosis/necrosis
was veriﬁed. The distribution of cell cycle phases of 3T3, HMEC and
RAW cells treated with nanogel at 0.1 and 0.5 mg/mL for 24 h is
shown on Fig. 4A. As could be observed no effect on HMEC and
3T3 cell cycle progression was veriﬁed, except for the 3T3 popula-
tion incubated with the higher nanogel concentration, where a
slight decrease of the G2 phase was observed. However, in RAW
cells, a highly signiﬁcant dose dependent cell cycle arresting was
veriﬁed on G1 phase. This increase of G1 population is correlated
with a reduction of the S and G2 phases, as may be observed on
the cell cycle distribution presented on Fig. 4B.
3.4. Evaluation of complement activation
In this assay the cleavage product of the C3 component was
used as a marker for complement activation by any pathway.
Therefore, by studying the degradation of the C3 factor we can
determine whether the nanogels have a potential effect on the
complement activation cascade. The western blot assay for the
C3 fragment detection was performed after incubation of the GC
nanogel (1 mg/mL) with human plasma. The results are shown in
Fig. 5A. The upper band of 115 kDa corresponds to the intact C3
factor and the one with 43 kDa to the main degradation product.
The protein degradation was quantiﬁed considering the intensity
of the band at 43 kDa normalized to the value obtained with the
positive control (cobra venom factor). As could be observed in
Fig. 5B the percentage of C3 cleavage product(s) was similar to
those found in the negative control, so it may be concluded that
the GC nanogel does not activate the complement system.
3.5. Murine macrophages cellular uptake
In order to investigate whether the nanogels are phagocytosed
by macrophages, ﬂuorescent nanogels were incubated with murine
macrophages. Fig. 6A and B illustrate the cellular uptake of FITC
labelled dextrin nanogel (used as a positive control of macrophages
uptake, as shown by Gonçalves et al. and NHS-Fluorescein labelled
GC nanogels, respectively (Goncalves et al., 2010). Interestingly,
the GC nanogel was poorly internalized by murine macrophages
as compared with dextrin nanoparticles.
3.6. Haemocompatibility studies
3.6.1. Haemolysis index
According to the Standard Practice for Assessment of Haemolytic
Properties of Materials from the American Society for Testing Materials
(ASTM F756-00, 2000) the nanogel was non-haemolytic at the
concentrations tested, since the haemolytic index is inferior to5% (Table 1), although a slight effect is observed for the higher
concentration.3.6.2. Whole blood clotting time
In this assay, human whole blood was allowed to clot in contact
with the GC nanogel to assess the nanomaterial likelihood to be
thrombogenic in vivo. As clotting occurs, more red blood cells are
retained in the clot, and therefore less haemoglobin is released
by lysis upon addition of distilled water. The results (Fig. 7)
showed that the nanogel samples exhibited a similar behaviour
to the negative control (PBS), thus being classiﬁed as non-
thrombogenic; conversely, as expected, the glass microspheres
showed the quickest clotting time.4. Discussion
Although GC is recognized as a highly biocompatible chitosan
derivative (Carreño-Gómez and Duncan, 1997), a deﬁnitive state-
ment on this matter requires further experimental evidences. Thus,
the purpose of the present work was to perform a comprehensive
study of the GC based-nanogel biocompatibility. The GC used for
nanogel synthesis, purchase from Sigma–Aldrich, were thoroughly
characterized in our previous work, due to the lack of consistent
data in literature. The amphiphilic polymer resultant from covalent
attachment of hydrophobic chains on the hydrophilic GC backbone
(100 kDa) self-assembles in water medium originating nanogels
with an average size of the 250 nm and positive surface charge
(+30 mV). (Pereira et al., 2013).
The metabolic activity studies show that the GC nanogel does
note reduce the mitochondrial activity overtime; however, cell
growth inhibition was observed in all cell lines. The HMEC cell pro-
liferation reduction (at 48 and 72 h incubation time) was found to
be dose dependent, while no such correlation was observed for 3T3
an RAW cells. Anitha et al. reported a similar dose independent
effect observed in two cell lines of ﬁbroblasts (L929, NIH3T3) after
48 h exposure to thiolated chitosan nanoparticles (Anitha et al.,
2011). Absence of cytotoxicity and cell growth inhibition effect in
L929 ﬁbroblasts treated with chitosan-g-poly(N-vinylcaprolactam)
nanoparticles was reported by Rejinold et al. after 24 h of incuba-
tion (Rejinold et al., 2011). The same was observed in this work for
the 3T3 cell line, after short incubation period (24 h). The HMEC
and RAW cell lines were clearly more susceptible to nanogel treat-
ment, mainly for later incubation periods. Equivalent RAW cell
growth inhibition rate was obtained by Kim et al. for NCTC 3749
macrophage cells (20–30%) treated with 0.1 mg/mL of mannosylat-
ed nanoparticles for 24 h (Kim et al., 2006). It is noteworthy that
fairly high concentrations of the nanogel were used in the current
study, purposely to detect toxic effects. Applications of the bioma-
terial are not likely to reach such concentrations in vivo, nor the
contact time with cells will be as long as the tested ones; hence
the results achieved can be considered indicative of the safety of
the material. The absence of the GC nanogel cytotoxicity was also
conﬁrmed by measuring the cell membrane integrity through
LDH leakage quantiﬁcation. According to Fotakis and Timbrell
(2006), the LDH leakage assay is not as sensitive as the MTT assay
for cytotoxicity detection, since it requires higher concentration of
the sample or longer incubation time. Although being a cell-type
dependent method, we did not observe signiﬁcant differences by
increasing the incubation time or varying the sample concentra-
tion. The apoptosis assay corroborate that GC nanogel did not
induce cell death by necrosis and/or apoptosis, in agreement with
LDH release results, since necrosis would result in the loss of cell
membrane integrity (Vermes et al., 1995). Moreover, the cell
cycle analysis demonstrated that any effect on HMEC and 3T3 cell
cycle progression was veriﬁed. However, in RAW cells a highly
Fig. 3. Flow cytometry analysis of Annexin V-FITC/PI double staining of (A) 3T3, HMEC and RAW cell lines, after incubation for 24 h with the nanogel or with H2O2 as positive
control, at different concentrations and periods of incubation for each cell line (0.5 mM for 6 h – RAW; 0.3 mM for 24 h – HMEC and 5 mM for 3 h – 3T3). The statistical
differences between negative control (25% of water content in cell culture medium) and remaining samples were obtained by a t-test and represented as (⁄). (B) Dot plots
correspond to the analysis of RAW cells and are shown as an illustrative example. Top left quadrant, dead cells (Annexin V/PI+); top right quadrant cells in a late stage of
apoptosis (Annexin V+/PI+); bottom right quadrant, apoptotic cells (Annexin V+/PI) and bottom left quadrant, viable cells (Annexin V/PI).
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phase, which may be due to phagocytic activity, and therefore
higher concentration of the nanogel inside the cells. Nevertheless,
as shown above bone marrow derived macrophages internalize GC
nanogel to little extent. Similar studies on the effect of drug loaded
GC nanoparticles on the cell cycle arresting have been reported.
Surprisingly, these studies usually just show the effect of the drug,
and no data regarding to the effect of the nanocarrier alone could
be found (Park et al., 2006).Depending on the nanoparticles administration pathways and
their physicochemical properties, they could induce different
immune reactions that are initiated with adsorption of opsonins
to the nanoparticles surface, triggering the complement system.
By itself, opsonization is not able to destroy the invaders but it acts
as a border guard priming the surface of nanoparticles for rapid
recognition and clearance by complement receptor bearing cells
such as blood monocytes and macrophages of the mononuclear
phagocyte system (MPS). (Denis, 2012; Peter and Moghimi, 2012)
Fig. 4. Cell cycle analysis data (A) of the 3T3, HMEC and RAW cells after 24 h of nanogel treatment at 0.1 and 0.5 mg/mL (NG0.1 and NG0.5, respectively); (B) Effect of the
nanogel on RAW cells cycle progression as representative example. Statistical differences between negative control group (25% of water content in cell culture medium) and
both nanogel concentrations were found by a t-test and represented as (⁄).
Fig. 5. Evaluation of GC nanogel (GC NG) complement activation through C3 protein cleavage. (A) Western blot membrane incubated with a mouse monoclonal antibody
against human C3 and a secondary polyclonal goat anti-mouse IgG antibodies conjugated with alkaline phosphatase. (B) Graphical representation of the % of cleavage of C3
protein induced by GC nanogel (GC NG) as compared to negative (C) and positive (C+) controls (PBS and Cobra venom factor, respectively).
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complement activation, all converge to the cleavage of the central
component C3 (Carroll, 2004). So, as human serum in the presence
of the GC nanogel revealed similar percentages of C3 cleavage pro-
duct(s) to those found in the negative control, could be concluded
that the GC nanogel does not activate the complement system.
Indeed, Bertholon et al. refers chitosan as a weaker activator of
the complement cascade. They showed that increasing the molecu-
lar weight of chitosan led to decreased complement activation,
reaching negligible levels. (Bertholon et al., 2006) Marchand et al.
also concluded that chitosan is a non-activating biomaterial; in
spite of binding anionic plasma and serum proteins like C3, it does
not led to complement activation (Marchand et al., 2010). As the
long systemic circulation half-life of the nanoparticles is dependenton their ability to avoid the capture bymacrophages of theMPS, the
development of ‘stealth’ nanoparticles is highly desirable. (Fang
et al., 2012) Interestingly, we found that GC nanogel was poorly
internalized by bone marrow derived macrophages as compared
with dextrin nanoparticles. (Goncalves et al., 2010) Sarmento
et al. also reported that chitosan coated solid lipid nanoparticles
were neglectfully internalizedwithin RAW264.7 cells, as compared
with uncoated solid lipid nanoparticles (Sarmento et al., 2011).
Indubitably this is a promising result since GC nanogel may thus
evade blood clearance and keep on circulation enough time to ﬁnd
the target site.
Charged particles readily interact with negatively charged cell
surface; probably, they can do so with negatively charged red
blood cells (RBCs). (Sarkar et al., 2013) Therefore, we investigated
Fig. 6. Confocal microscopy images of murine bone marrow derived macrophages treated with ﬂuorescent labelled (A) dextrin and (B) GC nanogels for 6 h.
Table 1
Blood haemolysis index after treatment with nanogel samples for
3 h at 37 C.
Sample Haemolytic index (%)
GC nanogel 0.5 mg/mL 3.183 ± 0.137
GC nanogel 0.1 mg/mL 1.423 ± 0.366
C+ (ultrapure water) 98.773 ± 0.816
Fig. 7. Whole blood clotting time for nanogel samples at 0.1 and 0.5 mg/mL. The
positive control (C+) used were glass microspheres and the negative (C) PBS. No
statistical differences were observed between negative control and nanogel
samples.
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to be non-hemolytic, even though both haemolytic and non-
haemolytic effects have been previously assigned to chitosan based
nanoparticles (Layek and Singh, 2013; Nogueira et al., 2013). The
GC nanogel was found to be non-haemolytic, and may also be con-
sidered non-thrombogenic, in agreement with He et al., who have
found that the positive charge of chitosan retarded thrombin gen-
eration and blood coagulation. (He et al., 2013).
5. Conclusion
The biocompatibility of GC nanogels was comprehensively
characterized. Although slightly reducing the growth rate of RAW
and HMEC cell lines such an effect could not be explained by cell
membrane compromising nor apoptosis/necrosis induction. A
more severe effect observed in the case of RAW cells could be at
least partially explained by the observed effect of cell cycle arrest;
however for the HMEC this was not the case, an issue that remains
to be clariﬁed. It must be remarked that fairly high concentrations
of the nanogel were used in these assays. Under physiological con-
ditions associated to a possible application of this material, lowerconcentrations and contact times should arise, such that we may
classify the GC nanogel as safe. In conclusion, the present study
demonstrate that the GC nanogel is able to be systemically
administered, since it did not activate the complement system,
evade the MPS, did not interact with RBC’s and was found to be
non-thrombogenic. These ﬁndings indicate that GC nanogel is a
promising biocompatible vehicle for drug delivery.
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